Qiagen has announced the QuantiFERON Monitor (QFM), a novel diagnostic for monitoring immune function. It is available in non-European markets for research use as an accurate marker of immune function in studies of immunosuppressive conditions, immune modulating therapies and recovery following transplantation.
Researchers from The Centenary Institute, Sydney, have announced a breakthrough in understanding the cause of stroke in young people. The leader of the research, Dr Xiangjian Zheng, said the stroke in question affects around five in every 1000 people, many of whom are diagnosed in their 30s and 40s.
Qiagen has announced the CE-IVD marking of its liquid biopsy-based companion diagnostic that analyses circulating nucleic acids obtained from blood samples to assess a genomic mutation in patients with non-small cell lung cancer (NSCLC).
US researchers have uncovered a 'pre-malignant' state in the blood that significantly increases the likelihood that an individual will develop blood cancers such as leukaemia, lymphoma or myelodysplastic syndrome.
Researchers at the Universidad Politécnica de Madrid (UPM) have found a new, low-cost way to enhance detection capacity of small concentrations of rotavirus - a sphere-shaped virus up to 75 nm in diameter that has the appearance of a wheel, seen from an electron microscope.
Australian, US and Dutch researchers have determined the molecular details of the interaction between the immune system and gluten that triggers coeliac disease.
Melbourne-based biotech company Starpharma has signed an expanded agreement with biopharma company AstraZeneca in the field of cancer medicine. The new agreement will see the application of Starpharma's dendrimer technology to a cancer drug from AstraZeneca's pipeline.
Fio Corporation's Deki Reader - a mobile in vitro diagnostic device - has demonstrated consistent interpretation of rapid diagnostic tests (RDTs) for multiple malaria strains in a field evaluation.
Scientists are using the latest in nano-flare technology to detect breast cancer cells early on.
Scientists from clinical intelligence company Empiriko have developed chemosynthetic liver technology which could enable the testing of drug candidates without using animals.
Researchers from Finland and Estonia have discovered novel biological markers that indicate an individual's risk of dying from any disease in the near future.
Prana Biotechnology has announced the results of its phase 2 clinical trial investigating the drug PBT2 as a treatment for Huntington disease.
Over 30 European universities, research institutes and companies are joining forces in a six-year, €85 million program to develop novel antibiotics against Gram-negative pathogens.
After one of the most intensive investigations in veterinary history for a single animal, what caused the death of Berlin Zoological Garden's polar bear, Knut, has been revealed.
Researchers at The University of Queensland (UQ) are working on a single-dose (shelf-stable) vaccine that could be used to prevent common cattle diseases and reduce vaccination costs.